Pharmexa receives US patent on the GV1001 vaccine for chemotherapy

26-Apr-2006

The US patent authorities have issued a patent to Pharmexa on the GV1001 vaccine. GV1001 is Pharmexa's peptide vaccine targeting telomerase, which is currently under preparation for Phase III trials in pancreatic cancer. Pharmexa already has issued and validated patents for the GV1001 vaccine in Europe and Australia.

Pharmexa's issued patent claims cover specific peptides, including the GV1001 vaccine, and their use in cancer immunotherapy. In addition, divisional patent applications have been filed in both Europe and the USA.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance